http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Vinblastine Sulfate가 Mouse 간세포내 소기관에 미치는 영향에 관한 연구
김재송,정호삼,이규식 한양대학교 의과대학 1988 한양의대 학술지 Vol.8 No.1
Vinblastine sulfate, isolated from the vinca, has been widly used in the therapy of Hodgkin's disease, breast cancer, neuroblastoma and choriocarcinoma. Vinblastine sulfate not only inhibits the formation of microtubule but also destructs preformed microtubule so that crystal bodies are formed in the cell by vinblastine sulfate treatment. Therefore vinblastine sulfate inhibits so profoundly the mitosis and transport of methbolites, the degenerative changes are occurred. Based on above mentioned, the author undertook the present study to pursue the effect of vinblastine sulfate on the cytoplasmic organelles of the hepatocytes. Albino mice, ICR strain, weighing 20 gm were used as experimental animals. The experimental animals were killed 4 days after administration of 12 mg/kg of vinblastine sulfate. The specimens obtained from the anterior lobe of the liver were prefixed in Millonig's solution and post-fixed in th 1% osmic acid. And then specimens were embedded in the Epon 812, stained with uranyl acetate and lead citrate, and observed with JEM 100B electron microscope. The results were as follows: 1. The cisternae of the rough endoplasmic reticulum were dilated, sacculated and irregularly arranged, and membrane bound ribosomes were detached. 2. Golgi complex was hypetrophied, and its forming face and maturing face were nt identified. 3. Some mitochondria were hypetrophied and their crest and double membranes were disappeared. 4. Numerous autophagic vacuoles, multivesicular bodies and lysosomes were observed. 5. Numerous lipid droplets wer also observed. Consequently, it is suggested that vinblastine sulfate would induce a deenerative changes in the cytoplamic organelles of the hepatocytes in mice.
손위형제 또는 자매가 있는 소아에서 Palivizumab 투여 여부에 따른 임상적 효과 분석
김진여,박지은,정민재,김재송,김수현,손은선 한국병원약사회 2018 病院藥師會誌 Vol.35 No.4
Background : Palivizumab is an intravenous monoclonal antibody which is used in the prevention of respiratory syncytial virus (RSV) infection. It is currently recommended for infants who are at high-risk for RSV infections due to preterm birth or other medical conditions such as congenital heart disease. Palivizumab is a humanized monoclonal antibody directed against an epitope in the antigenic site A of the protein F of RSV particles. Palivizumab is given once a month via intramuscular (IM) injection throughout the duration of the RSV season. Since palivizumab is known to have preventive effects against RSV infection for children with older siblings, the insurance coverage for palivizumab was expanded in October 2016. Methods : The electronic medical records of children under 2 years old who have older siblings who visited or were admitted to the Severance Hospital from October 2015 to May 2016 and from October 2016 to May 2017 were reviewed retrospectively. The data were then divided into two groups depending on the pilivizumab administration. Results : A total of 67 patients were enrolled in this study. The effectiveness in the reduction of hospitalization was statistically significant (p=0.009). Palivizumab decreased respiratory symptoms such as cough, rhinorrhea, and fever in patients with older siblings (p 0.05). Conclusions : In this study, palivizumab administration was effective in preventing RSV infection in infants with older siblings. Expanding palivizumab-prophylaxis administration to infants with older siblings may be effective in the prevention of upper respiratory infections.
호스피스 케어가 말기암환자 가족들의 죽음에 대한 인식 변화에 미치는 영향
계광원,김재송,원주희,이성옥,이채영,조성훈,박윤미,윤영미,이명숙,주선미,Gye Gwang-Won,Kim Jae-Song,Won Ju-Hui,Lee Seong-Ok,Lee Chae-Yeong,Jo Seong-Hun,Park Yun-Mi,Yun Yeong-Mi,Lee Myeong-Suk,Ju Seon-Mi 한국호스피스협회 2005 호스피스 학술지 Vol.5 No.2
The objective of this research is to provide the basic material for effective hospice care by analyzing the recognition of families who have terminally ill patients over death. To do so, this research is designed to investigate the general tendency toward death and changes after hospice care. To analyse the initial status of the recognition about the death, questionnaires were provided to the families of the terminally ill patients who were taken hospice care from June 1st, 2005 to September 10th, 2005 at Saemmul Hospice. The same questionnaires were distributed to research some changes of the recognition of the death after 3 weeks. As the Data Analysis Methodology, SPSS v.10.0 statistics program were utilized. The summary of this research is as follows. First, by gender, it is analyzed that women have more fear than men in terms of incompetence sense after death. By religion, Christians have less fear than other religious people in terms of fear toward after death and general sense of death. Second, those who experienced deaths of close family members, relatives, friends for the past 3 years have more fear toward the moment of death than those who did not experience it. Third, statistically valid difference was found in terms of fear toward the moment of death, fear toward incompetence, fear toward after death, and fear toward death before and after the hospice care was taken. Based on the result of this research, terminally ill patients' families facing death have shown significant differences on fear and incompetence before and after hospice care was offered. It is necessary that the hospice care should be settled more professionally by expanding the opportunities of hospice care and institutionalizing the system. In addition, hospice activities which are focused on providing hope after death and facing death with dignity and peace should be expanded increasingly as the family members who experienced deaths showed higher degree of fear and powerlessness and Christians have less fear toward death with the help of biblical influence. It is also required that hospice care specialized in recognizing the importance of terminal cancer patients and their families at the same time.
정선미,김재송,오명현,김수현,손은선 한국정맥경장영양학회 2017 한국정맥경장영양학회 학술대회집 Vol.2017 No.-
연구 배경 및 목적: 정맥주사용 혼합비타민은 비타민 결핍 예방 및 치료 목적으로 정맥영양수액 및 기초수액에 혼합하여 널리 사용된다. 정맥주사용 혼합비타민으로 인한 알레르기반응의 발생률은 0.1% 미만으로 알려져 있지만, 해당 의약품으로 인한 약물유해반응이 지속적으로 보고되고 있다. 본 연구에서는 국내 단일 상급종합병원에서의 자발적 보고 시스템으로 수집된 정맥주사용 혼합비타민의 약물유해반응(ADR, Adverse Drug Reaction) 사례를 분석하고 안전한 의약품 사용에 도움이 되고자 한다. 방법: 2005년 11월부터 2017년 5월까지 국내 단일 상급종합병원의 약물유해반응 보고 체계에 따라 보고되어 평가완료된 사례를 수집하였다. `보건복지부 분류코드 [316] 혼합비타민제(비타민A, D혼합제제를 제외)`에 속하는 정맥주사 의약품을 추출하여 World Health Organization-Uppsala Monitoring Centre (WHO-UMC) 기준에 따라 가능성 있음(possible) 이상에 해당하는 사례를 후향적으로 분석하였다. 연구결과: 혼합비타민으로 인한 약물유해반응으로 보고된 총 202례 중 엠비아이주사(MVI inj) 130건, 타미풀주(Tamipool inj) 68건, 삐콤헥사주(Beecom hexa inj) 4건이며, 처방건수 대비 보고율은 0.061%, 0.020%, 0.009%였다. 연도별 처방건수 대비 보고율은 전체 약물유해반응 보고건수가 증가함에 따라 같이 증가하였고 엠비아이주사가 가장 다빈도로 보고되었으며 2015년에는 0.107%로 높았다. 보고된 증상으로 피부 188건(50%), 호흡기 40건(11%), 위장관 40건(11%)이었으며 심각도에서 중대한(Serious) 약물유해반응이라고 평가된 증상은 호흡기 20건(33%), 피부 12건(20%), 전신반응 11건(18%) 순이었다. 대부분은 당일 처치 후 회복(103건, 51%), 자연회복(86건, 43%)이었으나 2건에서 각각 5일, 7일의 입원기간 연장이 있었다. 약물유해반응이 보고된 후 정맥주사용 혼합비타민 사용을 유지한 경우는 7건(3%)이었고 동일약제 사용 1건, 다른 약제로 변경은 6건이었다. 재투여 시 부작용이 발현한 경우는 5건(2%) 이었다. 고찰 및 결론: 본 연구는 비교적 안전한 의약품으로 여겨진 정맥주사용 혼합비타민 투여 후 나타난 부작용을 분석하였다. 의약품 부작용에 대한 관심을 바탕으로 적극적인 모니터링을 통해 약물유해반응을 최소화하고 이를 보고하여 안전한 의약품 사용 방안을 제안한다.